<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04261972</url>
  </required_header>
  <id_info>
    <org_study_id>1655</org_study_id>
    <nct_id>NCT04261972</nct_id>
  </id_info>
  <brief_title>Cell-free DNA in Hereditary And High-Risk Malignancies</brief_title>
  <acronym>CHARM</acronym>
  <official_title>Early Detection of Cancer in High-risk Patients Through Cell-free DNA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sinai Health System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Women's College Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>British Columbia Cancer Agency</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jewish General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CancerCare Manitoba</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>IWK Health Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to develop an effective, sensitive blood test that can detect early
      tumours in patients with known or suspected hereditary cancer syndromes (HCS). If this new
      blood test is accurate, it could be used to screen patients for cancer and allow for earlier
      cancer detection. The study will also use questionnaires and interviews to understand how
      patients feel about incorporating these tests into routine medical care, and the perceptions
      of the medical value of test results.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this protocol is to develop a method to detect early signs of cancer in
      'previvors' (people with HCS that do not yet have a cancer diagnosis). This will enable
      prediction of cancer onset so that patients and their doctors can make decisions to treat or
      prevent the cancers. HCS patients will be recruited from across Canada to provide blood
      samples before and after cancer diagnosis. In parallel, there will be development of a
      circulating tumour DNA (ctDNA) -based test to detect early stage cancer and evaluation on the
      cost-effectiveness and feasibility of integrating such screening protocols into routine
      clinical care. In concert, consultation with patients and health care providers will occur to
      create recommendations for use within clinical care.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Collection of biospecimens from 1500 HSC carriers.</measure>
    <time_frame>up to 4 years</time_frame>
    <description>Facilitate and streamline the collection, banking, and annotation of plasma samples and tumour tissue (if applicable) across Canada.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Collection of clinical data from 1500 HSC carriers.</measure>
    <time_frame>up to 4 years</time_frame>
    <description>Extract clinical data for all study participants from electronic medical records. Data collection will include family history and medical history.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Detection of early stage cancer in HCS patients using cfDNA.</measure>
    <time_frame>up to 4 years</time_frame>
    <description>Detect concentration of cfDNA circulating in the blood by shallow whole-genome sequencing, targeted panel analysis, and cfMeDIP.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of the clinical utility of a cfDNA test for HSC patients.</measure>
    <time_frame>up to 4 years</time_frame>
    <description>Conduct qualitative interviews with healthcare providers and patients.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of the optimal implementation of cfDNA in clinical practice.</measure>
    <time_frame>up to 4 years</time_frame>
    <description>Conduct a discrete choice experiment survey with HCS patient and providers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of cfDNA test implementation through cost-effectiveness analysis of cfDNA versus standard of care.</measure>
    <time_frame>up to 4 years</time_frame>
    <description>Conduct economic modelling using the economic evaluation guidelines from the Canadian Agency for Drugs and Technologies in Health.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Hereditary Cancer Syndrome</condition>
  <arm_group>
    <arm_group_label>CHARM</arm_group_label>
    <description>Patients identified with hereditary breast and ovarian cancer syndrome (germline BRCA1 or BRCA2 carrier) or Lynch syndrome (germline variant in EPCAM, MLH1, MSH2, MSH6, or PMS2).</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Next generation sequencing (NGS)</intervention_name>
    <description>NGS</description>
    <arm_group_label>CHARM</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Longitudinal blood plasma collected annually on patients. Archived formalin-fixed
      paraffin-embedded tissue or fresh frozen tissue from a biopsy or surgery is collected when
      applicable.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The population to be studied includes:

          1. Any individual that underwent clinical genetic testing for hereditary breast and
             ovarian cancer syndrome or Lynch Syndrome and was found to carry a detectable variant
             that is likely pathogenic or pathogenic.

          2. Any individual with a suspected cancer predisposition that has not yet received
             genetic testing.

          3. Any individual who received negative genetic test results but has a strong personal or
             family history of cancer.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Individual with any known or suspected hereditary cancer predisposition (i.e.
             individuals with an identified pathogenic or likely pathogenic variant in a cancer
             predisposition gene and/or a family history of cancer without an identified gene
             mutation) at any stage in their cancer journey (ie: cancer survivor, unaffected with
             cancer, current cancer patient).

          2. Individual must be greater than 18 years of age

          3. Individual must speak English or French to participate in the qualitative interview
             and/or survey

        Exclusion Criteria:

        1. Individuals that do not meet the outlined inclusion criteria.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raymond Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Princess Margaret Cancer Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leslie Oldfield, MSc.</last_name>
    <phone>613-532-9847</phone>
    <email>charm@uhnresearch.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>BC Cancer Agency</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Intan Schrader, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Leigh Murphy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IWK Health Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3K 6R8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Lynette Penney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sinai Health System</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raymond Kim, MD</last_name>
      <phone>416-586-4800</phone>
      <phone_ext>4220</phone_ext>
      <email>raymond.kim@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Raymond Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raymond Kim, MD</last_name>
      <phone>416-586-4800</phone>
      <phone_ext>4220</phone_ext>
      <email>raymond.kim@uhn.ca</email>
    </contact>
    <contact_backup>
      <last_name>Leslie Oldfield, MSc</last_name>
      <phone>613-532-9847</phone>
      <email>leslie.oldfield@uhnresearch.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Raymond Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Women's College Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5S 1B2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Marcus Bernardini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michelle Jacobson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>William Foulkes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Basik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 2, 2020</study_first_submitted>
  <study_first_submitted_qc>February 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2020</study_first_posted>
  <last_update_submitted>February 7, 2020</last_update_submitted>
  <last_update_submitted_qc>February 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Circulating tumour DNA</keyword>
  <keyword>Cell-free DNA (cfDNA)</keyword>
  <keyword>Hereditary cancer syndrome</keyword>
  <keyword>Cancer</keyword>
  <keyword>BRCA1</keyword>
  <keyword>Lynch syndrome</keyword>
  <keyword>Hereditary breast and ovarian cancer</keyword>
  <keyword>Liquid biopsies</keyword>
  <keyword>BRCA2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplastic Syndromes, Hereditary</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

